Drug intelligence / Profile preview

CRMD-005

Development stage: Preclinical
Lead developer: CorMedix
Modality: Nanoparticles → Drug Delivery Systems, Small Molecules
Administration: Intravenous

Overview

CRMD-005 is a proprietary nanoparticle formulation of taurolidine developed by CorMedix for the treatment of pediatric cancers, including neuroblastoma and osteosarcoma. The formulation utilizes NanoProteagen's NanoPro™ nanoparticle delivery technology, which is designed to selectively target tumor cells and minimize systemic toxicity. CRMD-005 is being investigated in preclinical studies, both as a monotherapy and in combination with vincristine, in collaboration with the Pediatric Oncology Experimental Therapeutics Investigators' Consortium (POETIC).

Other names: taurolidine nanoparticle formulation

Beyond the preview

Go deeper on CRMD-005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CRMD-005.

Explore the full profile